Targeting– tag –
-
CRISPR Therapeutics Diversifies Pipeline into In Vivo Gene Editing and Off-the-Shelf CAR-T Cell Therapies, Leveraging Casgevy Commercialization Experience
Venture Atlas USA Overview CRISPR Therapeutics is strategically diversifying its pipeline, leveraging its commercialization experience with Casgevy, into in vivo gene editing programs (CTX310, CTX320, CTX340, CTX460) and allogeneic off-t... -
IPS HEART’s iPSC-Derived Cell Therapy ISX9-CPC Secures FDA Rare Pediatric Disease Designation, Advancing Clinical Trials for Cardiac & Rare Muscle Disorders
Facebook (IPS Heart) USA Overview IPS HEART announced that its iPSC-derived cell therapy, ISX9-CPC, received Rare Pediatric Disease Designation (RPDD) from the FDA. Targeting cardiac and rare muscle disorders, this designation positions ... -
CRISPR Frontiers 2026: Innovations in DSB-Independent Editing and Delivery Systems Boost Genome Editing Precision and Stability
Addgene Blog USA Overview The 'Genome Engineering: CRISPR Frontiers 2026' conference reported significant evolution in CRISPR technology towards precise, double-strand break (DSB)-independent editing. Researchers are focusing on enhancin... -
NurExone Accelerates U.S. Market Entry with GMP Exosome Manufacturing Partnership with Made Scientific, Targeting First Batch by H1 2027
BioPharma BoardRoom USA Overview Exo-Top Inc., a U.S. subsidiary of NurExone Biologic Inc., has signed an MOU with Made Scientific, Inc. for a GMP exosome manufacturing partnership in the U.S. This strategic alliance aims to accelerate N... -
Moffitt Cancer Center’s Dr. Yvonne Chen Proposes Novel Strategies to Overcome Tumor Microenvironment Barriers in Solid Tumors with Logic-Gated CAR T-Cells
Moffitt Cancer Center USA Overview Dr. Yvonne Chen of Moffitt Cancer Center has discussed new strategies to enhance CAR-T cell therapy for solid tumors, focusing on precise targeting with logic-gated CAR-T cells and reprogramming the tum... -
CRDWC 2026 Symposium to Address CAR-T Challenges in Solid Tumors: Focus on Design, Manufacturing, and Safety Strategies
CRDWC 2026 (Cancer Research and Development Conference 2026) Unknown Overview The 2026 Cancer Research and Development Conference will host a symposium dedicated to expanding CAR-T cell therapy from hematological malignancies to solid tu... -
XsellSmart Biopharmaceutical Completes Patient Enrollment in Phase 1 Trial for Universal Cell Therapy XS411 in Parkinson’s-Type Multiple System Atrophy
VCBeat China Overview XsellSmart Biopharmaceutical announced the completion of full participant enrollment in its Phase 1 registrational clinical trial for XS411, a universal cell therapy targeting Parkinson's-type multiple system atroph... -
UCSD Advances Next-Gen CAR-T & Gamma Delta T-Cell Therapies for Solid Tumors in Multiple Phase 1 Clinical Trials
UCSD USA Overview UCSD is actively pursuing multiple Phase 1 clinical trials for next-generation cell therapies targeting advanced solid tumors. Featured trials include FT825/ONO-8250, an off-the-shelf HER2 CAR-T, and A2B395, an allogene... -
Clinical Progress of Engineered Cellular Immunotherapies for Autoimmunity: Diverse Modalities Pioneer New Treatment Avenues
PMC - NIH USA Overview Clinical development of engineered cellular immunotherapies for autoimmune diseases is rapidly advancing, poised to offer novel therapeutic options. Diverse modalities, including CAR-T cells, CAR-NK cells, and TCR-... -
Voyager Therapeutics Advances Two Tau-Targeted Alzheimer’s Therapies Towards Key Clinical Milestones
NeurologyLive USA Overview Voyager Therapeutics announced its progression of two innovative therapeutic candidates targeting tau protein, a key pathological hallmark of Alzheimer's disease, toward significant clinical milestones. These c...
